Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025Immunology

Targeting Neuropilin‐1 to Enhance Immunotherapy in Melanoma: Reducing Peripheral Treg‐Mediated Immunosuppression and Tumour Progression

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSomlata KhamaruKTKshyama Subhadarsini TungSCSubhasis Chattopadhyay

Discussion

Loading...

Member takes

Overview

Inhibition of Neuropilin‐1 enhances Treg-mediated immunosuppression reduction in melanoma, suggesting immunotherapy advancements.

Key Points

  • Inhibition of NRP1 reduced Treg-mediated immunosuppression and tumor growth in melanoma.
  • Elevated IL-6, IL-2, and IL-17A levels correlated with NRP1 expression in the majority of melanoma samples.
  • Analysis of peripheral Tregs revealed activation of the PI3K/AKT pathway after NRP1 inhibition in vitro.
  • Targeting NRP1 offers potential for improved melanoma treatment and enhanced immune response.

Cite This Study

Khamaru et al. (2025) studied this question.

synapsesocial.com/papers/692b9da91d383f2b2a37a4e5https://doi.org/10.1111/imm.70072
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neuropilin-1 expression by solid tumors impairs CAR T cell function2025
  2. 2Nrf2 as a negative regulator of CD8+ T-Cell-mediated anti-melanoma responses 36132025
  3. 3Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma.2025
  4. 4Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression2025
  5. 5The S1P/S1P1 Signaling Axis Plays Regulatory Functions in the Crosstalk Between Brain-Metastasizing Melanoma Cells and Microglia2025